Janssen H L, Brouwer J T, van der Mast R C, Schalm S W
Department of Internal Medicine II (Section Hepatology), University Hospital Dijkzigt, Rotterdam, The Netherlands.
J Hepatol. 1994 Aug;21(2):241-3. doi: 10.1016/s0168-8278(05)80402-7.
We report on two attempted suicides and one successful suicide during or shortly after alfa-interferon therapy for chronic viral hepatitis. While on therapy, all three patients developed a psychiatric disorder leading to their suicidal behavior. In a survey of 15 European hospitals, three cases of attempted and two of successful suicide during alfa-interferon therapy for chronic viral hepatitis, were additionally reported. None of the patients had a psychiatric history. Alfa-interferon is known to lead to neuropsychiatric symptoms, and our observations strongly suggest that these mental disorders could lead to suicidal behavior. Therefore it is important that physicians, patients and their families are informed about the potential risk of the emotional and psychiatric disturbances that can occur during alfa-interferon therapy.
我们报告了两例在α-干扰素治疗慢性病毒性肝炎期间或治疗后不久的自杀未遂事件以及一例成功自杀事件。在治疗期间，这三名患者均出现精神障碍，导致他们产生自杀行为。在一项对15家欧洲医院的调查中，另外报告了三例在α-干扰素治疗慢性病毒性肝炎期间自杀未遂和两例成功自杀的病例。所有患者均无精神病史。已知α-干扰素会导致神经精神症状，我们的观察结果强烈表明，这些精神障碍可能导致自杀行为。因此，告知医生、患者及其家属关于α-干扰素治疗期间可能发生的情绪和精神障碍的潜在风险非常重要。
